SPONSORING FUNDAMENTAL UNIVERSITY RESEARCH
Academic Research Sponsorships.
At Cubed Biotech, we believe that the future of psychedelic medicine depends on rigorous, university-led research. That’s why we proudly sponsor leading neuroscientists whose work uncovers the mechanisms by which psychedelic compounds restore mental health"⸻
University of Cambridge
🌐 Duke University & University of Cambridge
Breakthrough PTSD Remission with 5-MeO-DMTThrough a cross-institutional collaboration with Duke’s Dr. Paul Seli and Cambridge’s Dr. Anya R., Cubed is helping advance research into the fast-acting therapeutic potential of 5-MeO-DMT. In a recent case, their team documented full remission of PTSD in a female subject following guided 5-MeO-DMT therapy—one of the first real-world insights into its impact on trauma-related brain function. The research now explores how 5-MeO-DMT modulates the Default Mode Network and fear processing centers, with implications for future treatment-resistant trauma therapies.
Duke University
Our sponsorship of Paul Seli, Ph.D’s study is into the effect of psilocybin on political partisanship has begun at Duke University. Dr. Seli will run those who self-identify as being on the "right" or "left" can express more compassion and understanding to "the other side" after therapeutic sessions of psilocybin.
McGill University
Unlocking Psilocybin’s Effects on Self-Esteem and Resilience
In partnership with McGill and CQDM, we sponsor the research of Dr. Rosemary Bagot, whose lab investigates how psilocybin enhances neural circuits linked to self-reward and self-worth. Her team has identified plasticity in medial prefrontal cortex pathways that may explain psilocybin’s profound impact on mood and motivation. This foundational research may lead to novel treatments for depression, trauma, and addiction grounded in neurobiological self-esteem repair.
our steps
R&D
Why it Matters
• Mechanistic Validation: These studies inform Cubed’s drug development programs with real biological insight. • Biomarker Discovery: Our sponsored labs explore objective measures of psychedelic response. • Translational Impact: Findings support Cubed’s clinical protocols and regulatory pathways.
Bridging the Gap : Research vs. Commercialization
By supporting research at world-class institutions like McGill University, Duke University, and the University of Cambridge, we help bridge the gap between molecular insight and therapeutic application—fueling the next generation of psychedelic-based treatments.